Morning Versus Bedtime Dosing of Antihypertensive Medication

Официальное название

Morning Versus Bedtime Dosing of Antihypertensive Medication in Grade 1 Day-night Hypertension: a Multicenter Randomized Controlled Trial (Dosing-Time Trial)

Обзор

Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently. The investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.

Вмешательства

• Препарат Alisartan, Amlodipine besylate
  Drugs will be taken once daily at 6:00-10:00.
• Препарат Alisartan, Amlodipine besylate
  Drugs will be taken once daily at 20:00-24:00.

Первичные конечные точки

• Nighttime systolic BP reduction in mmHg [Срок оценки: 24 weeks]

Вторичные конечные точки (9)

• Daytime systolic BP reduction in mmHg, 24-Hour systolic BP reduction in mmHg, Home systolic BP reduction in mmHg [Срок оценки: 24 weeks]
• Brachial-ankle pulse wave velocity reduction in cm per second [Срок оценки: 12 and 24 weeks]
• Ambulatory night-to-day BP ratio change in percent; proportions of non-dippers in percent, morning systolic blood pressure in mmHg, [Срок оценки: 8 weeks and 24 weeks]
• Urinary albumine-to-creatinine ratio change in mg/mmol [Срок оценки: 12 weeks and 24 weeks]
• change in prevalence of left ventricular hypertrophy defined based on electrocardiogram [Срок оценки: 12 weeks and 24 weeks]
• change in prevalence of left ventricular hypertrophy defined based on echocardiography [Срок оценки: 24 weeks]
• Serum uric acid in umol/L [Срок оценки: 24 weeks]
• The difference in daytime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks [Срок оценки: 24 weeks]
• The difference in nighttime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks [Срок оценки: 24 weeks]

Критерии участия

Критерии включения

• Male or female patients aged 18-70 years old;
• Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks;
• In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP < 100 mmHg;
• The average 24-hour systolic BP ≥130mmHg, daytime systolic BP ≥ 135 mmHg, and nighttime systolic BP ≥ 120 mmHg;
• The average of bilateral brachial-ankle pulse wave velocity ≥14m/s;
• Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself.

Критерии исключения

• Secondary hypertension;
• Concomitant obstructive sleep apnea (STOP-BANG score ≥ 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP;
• Need to work at night;
• Ambulatory BP monitoring was invalid (<70% valid readings, or <20 daytime readings or <7 nighttime readings);
• Concomitant diseases that need taking medications influencing BP;
• Coronary heart disease, myocardial infarction or stroke within recent 6 months;
• Atrial fibrillation or frequent arrhythmia;
• Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine ≥176 µmol/L; and plasma potassium ≥5.5 mmol/L or ≤3.5mmol/L;
• Pregnant or lactating women;
• Contraindications of angiotensin II receptor blocker or calcium channel blocker;
• Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Ruijin Hospital — Шанхай

Идентификаторы

NCT: NCT05089448 · Dosing-Time Trial20210118

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗